Pomerantz LLP Initiates Class Action Against AeroVironment, Inc. – AVAV

AeroVironment (AVAV) is facing a securities class action filed over allegations of materially misleading statements tied to the U.S. Space Force’s SCAR program. The lawsuit highlights major stock declines after program setbacks—down $61.97 (-15.77%) on Jan. 20, 2026 following a stop-work order, then down $43.93 (-17.42%) on Mar. 2 after SCAR was reportedly reopened/reassessed, and down another $13.84 (-6.24%) on Mar. 11 after Q3 results including a $151.3M goodwill impairment and a SCAR contract termination that requires recompeting. The filing underscores heightened uncertainty around management’s revenue-growth assurances and the company’s defense contract outlook.

Analysis

This is a fundamental reset, not just a litigation headline. The market is repricing AVAV from a single-program growth story to a lower-quality, more substitutable revenue stream, which usually means lower forward multiples and a bigger EPS drawdown than the top-line miss alone suggests because engineering and overhead were built for scale that may not come back.

The key second-order effect is procurement architecture: once a defense customer moves from bespoke to diversified/COTS sourcing, the incumbent loses pricing power, follow-on unit economics, and timing control. That shifts bargaining power toward modular vendors and system integrators with broader catalogs, while making AVAV’s BlueHalo acquisition look more fragile—goodwill write-down risk can keep compressing sentiment even after the legal process fades.

The lawsuit is mostly a slow-moving overhang; the real catalyst is whether the Space Force awards anything material on a multi-vendor basis over the next 1-3 quarters. If management cannot quantify SCAR replacement or margin recovery by the next earnings call, the stock likely remains a show-me story for 6-18 months. Contrarian view: some of the damage may already be in the stock, so the cleaner short is not the filing itself but any rally that ignores the probability of a smaller, lower-margin replacement program.

Key Decisions for Investors

• Short AVAV on any 5-10% relief rally over the next 1-4 weeks; thesis is continued multiple compression as the market prices a lower-quality backlog and potential further guidance cuts.
• Buy 1-3 month AVAV put spreads rather than naked puts to express downside from the procurement reset; risk/reward improves if the stock re-tests the post-event lows before next earnings.
• Pair trade: long KTOS / short AVAV over the next 1-3 months to own the more diversified defense-tech platform while fading the single-program concentration and litigation overhang in AVAV.
• If already long AVAV, tighten risk ahead of the next earnings call; cover at any credible disclosure of SCAR backfill or amended award terms that imply >20% revenue recovery within 2 quarters.
• Watch item, not a trade yet: any evidence that the Space Force is formalizing a multi-vendor or COTS framework. If confirmed, it is a structural negative for AVAV but a positive read-through for modular defense suppliers and integrators.